Industry Monthly
August 2026 Industry Monthly
A monthly digest of policy, market, and technology developments across the pharmaceutical industry, based on public sources.
Policy & Pricing
Approved Drugs Await Launch in Japan as Western Firms Weigh Low Pricing (Nikkei)
On August 23, 2026, the Nikkei carried an article headlined "Cancer and diabetes: approved new drugs delayed to market — are US and European firms wary of low prices?" The article is behind a paywall and we were able to verify only the headline and lead, so we limit ourselves to that. The lead describes medicines approved in Japan that have yet to launch while reimbursement pricing remains undecided, and attributes this in part to caution among US and European manufacturers about Japanese price levels. Readers should consult the original article for the details and figures.
Source: Nikkei (August 23, 2026)Expert's View
When a gap opens between approval and launch, the practical result for patients is a treatment that is formally permitted but not actually obtainable. Discussion of drug lag tends to focus on delays in starting development or filing; how much delay occurs after approval is harder to gauge from published statistics alone. We note this as a point raised in the reporting, not as something we have independently quantified.
MHLW-Funded Study Reviews Rules on Drug Product Names and Packaging
A report from the MHLW-funded study "Research on medication safety relating to the product names and packaging of prescription drugs" (FY2024-FY2026; principal investigator Sachiko Watanabe, Shiraoka Chuo General Hospital) is available in the ministry's public research database. Drawing on medication-error cases such as look-alike/sound-alike names, mix-ups involving extended-release formulations, and labelling gaps on insulin and potassium products, it examines whether the existing notification framework needs revision. Points under discussion include required content on PTP blister sheets, standardisation of barcode labelling, and whether English product names should remain optional. The study runs to FY2026, so the current report represents work in progress.
Source: MHLW Health Sciences Research DatabaseExpert's View
Packaging and naming rules are an unglamorous area, but when a mix-up occurs it is front-line clinicians and patients who bear the consequences. Making English product names optional cuts both ways in settings with growing numbers of foreign patients and multinational staff, and a single blanket answer is hard to justify. The study is still under way and has reached no conclusion, but the approach — accumulating field evidence before changing the rules — is worth following.
Market & Business
Japan's Top Seven Drugmakers Post 17.3% Revenue Growth in Q1 FY2026
For the April–June 2026 quarter, Japan's seven major pharmaceutical companies reported combined revenue of 3,078.8 billion yen, up 17.3% year on year, and operating profit of 611.5 billion yen, up 29.0%. Six of the seven grew revenue, with Ono Pharmaceutical the exception. Astellas roughly doubled operating profit (up 94.9%) on the strength of its priority products, while Shionogi grew revenue 63.7% through M&A. A weaker yen also supported the results.
Source: AnswersNews (August 17, 2026; compiled from company results announcements)Expert's View
The double-digit growth is real, but it is concentrated in a narrow set of drivers: priority products, acquisitions, and currency. The structural erosion of domestic revenue from existing products under repeated price revisions has not changed, so it would be a misreading to treat strong headline results as evidence that the domestic business itself has strengthened.
Foreign Firms Reach 49.3% of Japan's Drug Market in 2025, Majority in Sight
According to IQVIA Japan (covering the top 100 companies, roughly 95% of the market), the share held by 33 foreign-affiliated companies — Chugai included — rose from 46.6% in 2020 to 49.3% in 2025, close behind the 50.7% held by 67 domestic companies. With a compound annual growth rate of 3.8% for foreign firms against 1.7% for domestic ones, commentators suggest the foreign share may pass 50% during 2026. Foreign companies account for 85% of the 674.3 billion yen in projected peak sales from the 55 new active ingredients launched in 2025.
Source: AnswersNews (August 18, 2026; reporting based on IQVIA Japan data)Expert's View
The share crossover matters less than the finding that foreign companies account for 85% of new-drug value. If most products entering Japan originate abroad, the practical work of supply, distribution and medical information inside Japan will carry increasing weight. Note that these figures reach us through secondary reporting; we have not accessed the underlying dataset.
Japan's Drug Market Up 3.7% in Q1 FY2026; Mounjaro Tops 50 Billion Yen
Japan's pharmaceutical market reached 2,986.8 billion yen in April–June 2026, up 3.7% year on year. By channel, hospitals with 100 or more beds accounted for 1,464.2 billion yen (up 4.8%), clinics under 100 beds 500.3 billion yen (up 1.5%), and pharmacies and others 1,022.3 billion yen (up 3.2%). Oncology led by therapeutic class at 581.5 billion yen (up 8.8%). By product, Keytruda (58.6 billion yen), Mounjaro (50.6 billion yen, up 126.2% and above 50 billion yen for the first time in a quarter) and Dupixent (37.4 billion yen) ranked highest.
Source: AnswersNews (August 18, 2026; reporting based on pharmaceutical market statistics)Expert's View
Growth is concentrated in the hospital channel, in oncology, and in metabolic products administered by self-injection - all areas that presuppose temperature control and managed dosing schedules. Market growth therefore translates directly into heavier requirements for distribution and home-based management. That the clinic channel grew only 1.5% is also not a trivial signal when viewed from the perspective of community healthcare.
Ten Major Drugmakers: Domestic Sales Running About 2% Ahead of Last Year
Domestic revenue at ten major pharmaceutical companies is currently running about 2% ahead of the same period last year. The seven companies with March year-ends recorded 461.0 billion yen for April-June 2026, down 0.5% year on year, while the three with December year-ends recorded 509.7 billion yen for January-June 2026, up 4.0%. Six of the ten grew domestic revenue and four declined; Shionogi rose 137.3% (roughly 2.4 times) on the contribution of its acquisition. These are reported results to date, not full-year guidance.
Source: AnswersNews (August 19, 2026)Expert's View
Consolidated quarterly results show double-digit growth, yet domestic revenue is up only around 2% — and slightly down for the March-year-end group. Growth is coming from overseas operations and currency effects, while domestic plans assume continued price revisions and generic substitution. Placing the figures side by side makes clear that companies are not simply capturing the 3.7% growth recorded by the domestic market in the same quarter.
* This report is edited by Yap Inc. based on publicly available sources. “Expert’s View” reflects the perspective of CEO Masaya Yamamoto (a NewsPicks Expert). Please refer to the original source for details on each item.
View More News